NCT03560973View on ClinicalTrials.gov

A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM

PHASE2CompletedINTERVENTIONAL

Enrollment

164

Participants

Timeline

Start Date

December 22, 2016

Primary Completion Date

July 30, 2018

Study Completion Date

July 20, 2022

Conditions

Mesothelioma

Interventions

DRUG

Gemcitabine

ramucirumab/ placebo was added to gemcitabine

DRUG

Ramucirumab

ramucirumab/ placebo was added to gemcitabine

Trial Locations (1)

42123

Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia

All Listed Sponsors

lead

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER

NCT03560973 - A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM | Biotech Hunter | Biotech Hunter